%0 Journal Article
%T Integration of genome-scale metabolic networks into whole-body PBPK models shows phenotype-specific cases of drug-induced metabolic perturbation
%A Christoph Thiel
%A Henrik Cordes
%A Lars Kuepfer
%A Lars M. Blank
%A Vanessa Baier
%J Archive of "NPJ Systems Biology and Applications".
%D 2018
%R 10.1038/s41540-018-0048-1
%X PBPK-GSMN Multiscale modeling workflow. Preparations and input: On the organism level, a comprehensive drug-specific whole-body physiologically based pharmacokinetic (PBPK) model is developed and validated with human pharmacokinetic (PK) data. On the cellular scale, a human genome-scale metabolic network (GSMN) reconstruction is used together with omics data to establish an organ-specific GSMN model and a reference flux distribution. PBPK-GSMN combination: The developed whole-body PBPK model is used to estimate the in vivo organ-specific drug metabolism as time-resolved reaction rates including the absorption, distribution, metabolism, excretion (ADME) processes. The organ-specific GSMN model is extended with the drug-specific xenobiotic metabolism (Table (Table1).1). PBPK-derived xenobiotic reaction rates are iteratively used to constrain the xenobiotic reaction rates in the organ-specific GSMN model. A dynamic version of the minimization of metabolic adjustment algorithm (dMOMA) is used to calculate altered flux distributions in the drug perturbated organ-specific GSMN. Prediction of cellular responses: The combined multi-scale PBPK-GSMN model can be used to predict organ-specific drug-induced metabolic perturbations, resulting in altered intracellular and extracellular reactions rates. The combined model allows the explicit consideration of specific dosing schemes, patient physiology, and genetic characteristic
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827733/